RADNOR,
Pa., Dec. 13, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, announced
their 2023 Annual Meeting of Stockholders (the "Annual Meeting") to
be held on December 19, 2023, at 11:00 a.m., Eastern
Time, in virtual-only format at
https://www.cstproxy.com/nrxpharma/am2023.
Management will discuss the items detailed in the Proxy
Statement, including the election of Janet
Rehnquist, a widely respected attorney with more than 25
years of experience in highly regulated industries, particularly
healthcare, as a member of the Company's Board of Directors.
In addition to items in the Proxy, Management will discuss the
planned spinoff of the IV Ketamine focused company, Hope
Therapeutics, Inc. The company is envisaged to be initially
owned by NRx Pharmaceuticals and individual NRx shareholders via a
dividend (or similar mechanism), along with new investors.
The company encourages stockholders and other interested parties
to attend this virtual meeting.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain, and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen Pharmaceuticals around
the development and marketing of NRX-101 for the treatment of
suicidal bipolar depression. NRX-101 additionally has potential to
act as a non-opioid treatment for chronic pain.
NRx has recently announced plans to submit a New Drug
Application for ketamine in the treatment of suicidal depression,
based on results of well-controlled clinical trials conducted under
the auspices of the US National Institutes of Health and newly
obtained data from French health authorities, licensed under a data
sharing agreement. NRx was awarded Fast Track Designation for
development of ketamine (NRX-100) by the US FDA as part of a
protocol to treat patients with acute suicidality.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-provides-notice-of-annual-meeting-of-shareholders-302014650.html
SOURCE NRx Pharmaceuticals, Inc.